Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS

Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS

BackgroundTimely identification of drug-induced Parkinson-like events is essential to improve clinical management and enhance patients’ quality of life. However, there is a significant lack of studies addressing these events in real-world settings.MethodsTo bridge this gap, we analyzed adverse event...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ke Wang, Junyan Chen, Mingquan Huang, Xinhao Zeng, Xiaoqun Ren, Xiuqiong Liu, Chao Tao, Liuxuan Yang, Jinlu Shang, Meiling Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pharmacology
Subjects:	Parkinson-like events pharmacovigilance drug safety antiparkinsonian agents adverse event FAERS
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1529260/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024-11-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database
by: Zhao YC, et al.
Published: (2024-11-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database
by: Hong Pan, et al.
Published: (2024-12-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Youqi Huang, et al.
Published: (2025-01-01)

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database
by: Wan Xiong, et al.
Published: (2024-11-01)

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system
by: Yu Zhang, et al.
Published: (2024-12-01)

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database
by: Ya-Jun Zhang, et al.
Published: (2024-12-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database
by: Jiancheng Qian, et al.
Published: (2024-12-01)

Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
by: Yifan Hong, et al.
Published: (2024-12-01)

Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database
by: Yanping Shu, et al.
Published: (2024-12-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib
by: Yi Yin, et al.
Published: (2024-11-01)

Signal detection and analysis of adverse events associated with Genvoya® based the FAERS database
by: Chengliang Wang, et al.
Published: (2024-12-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Drug-induced hearing disorders: a disproportionality analysis of the FAERS database
by: Baojian Li, et al.
Published: (2024-11-01)

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis
by: Heng Chen, et al.
Published: (2024-12-01)

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
by: Xianyu Dai, et al.
Published: (2025-01-01)

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
by: Qian Qiao, et al.
Published: (2025-01-01)

Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
by: Qinyun Xu, et al.
Published: (2025-01-01)

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
by: Hui Gao, et al.
Published: (2025-01-01)

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
by: Zhishen Ruan, et al.
Published: (2025-01-01)

Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database
by: Jing Luo, et al.
Published: (2024-11-01)

Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
by: Wenwen Zhang, et al.
Published: (2025-01-01)

Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004–2023)
by: Xiao-Dong Chen, et al.
Published: (2024-12-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)